- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07237594
IL-17 차단을 통한 irAEs 감소 (REPLAY) (REPLAY)
IL-17 차단을 이용한 면역관련 이상반응 위험 감소의 타당성 연구
The primary objective of this study is to determine the safety and feasibility of administering an IL-17A (human IgG1κ) monoclonal antibody, (Secukinumab, Cosentyx®) to participants with metastatic melanoma who have previously received immune checkpoint inhibitor (ICI) therapy, experienced an immune related adverse event (colitis, hepatitis, skin rash, psoriatic arthritis) to ICI, and are re-initiating ICI therapy.
연구 개요
상세 설명
Participants will receive pre-treatment (pre-ICI) with secukinumab (300mg) within 1 to 7 days prior to the initial ICI dose. Participants will then resume ICI therapy (the specific ICI agent and dose are determined by the treating physician per their standard practice). Participants will receive secukinumab weekly for the first 4 weeks, and then once every 4 weeks thereafter until grade 3 side effect occurs or ICI is discontinued.
Participants will have AE (adverse event) assessments at each study visit. Disease assessments via CT scans will be performed every 12 weeks with iRECIST/RECIST. Research blood samples and tumor tissue will be collected. All participants will be followed by phone call or medical record review for survival for up to three years. Participants who come off for reasons other than disease progression will also be followed with CT scans every 12 weeks until progression for up to two years.
연구 유형
등록 (추정된)
단계
- 1단계
연락처 및 위치
연구 연락처
- 이름: Emily Bolch
- 이메일: emily.bolch@duke.edu
연구 연락처 백업
- 이름: April Salama, MD
- 전화번호: +1 919 681 9507
- 이메일: april.salama@duke.edu
연구 장소
-
-
North Carolina
-
Durham, North Carolina, 미국, 27710
- 모병
- Duke University Health System
-
연락하다:
- April Salama, MD
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion criteria:
-
Histologically confirmed advanced metastatic melanoma
-
Participants of any gender who are at least 18 years of age on the day of signing informed consent
-
Participants must be planned or scheduled by their treating physician to receive PD-1 therapy or PD-1 plus anti LAG3 or PD-1 plus anti CTLA-4 therapy as standard of care. Patients should either be restarting the same ICI regimen which contributed to the prior toxicity or have a clinical need to escalate to doublet (combination) ICI therapy, plan for therapy should be reviewed by the PI of this study.
-
Participant (or legally acceptable representative if applicable) provides written informed consent for the trial
-
Participant must have had prior treatment with ICI therapy (either PD-1 therapy or PD-1 plus anti LAG3 or PD-1 plus anti CTLA-4 therapy as standard of care) and experienced grade 2 or higher immune-related colitis, hepatitis, or skin rash leading to treatment interruption or discontinuation or requiring steroid administration (systemic or topical).
- Note that patients who experience more than one irAEs are eligible to participate
-
Adequate organ function as defined below. Standard of care labs drawn within 42 days prior to consent may be used for the purposes of determining eligibility.
- Absolute Neutrophil Count (ANC) ≥ 1500/µL
- Platelets ≥ 100,000/µL
- Hemoglobin* ≥ 9.0 g/dL or ≥ 5.6 mmol/L *Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within the previous 2 weeks
- AST/ALT 2.5x upper limit of normal
Exclusion Criteria:
-
Uveal melanoma
-
Any participants known to be pregnant or breastfeeding.
-
Known diagnosis of immunodeficiency or receiving chronic systemic steroid therapy (in doses exceeding 10 mg daily of prednisone or equivalent), or any other form of immunosuppressive therapy within 7 days prior to first research biopsy
-
Patients with symptomatic CNS metastases and/or carcinomatous meningitis
- Patients with asymptomatic, clinically stable CNS metastases are allowed provided they do not require steroid treatment
-
History of or active (non-infectious) pneumonitis that required steroids
-
Active infection requiring systemic therapy
-
Known history of Human Immunodeficiency Virus (HIV) infection
-
Known history of Hepatitis B or known active Hepatitis C virus infection. NOTE: no testing for Hepatitis B or Hepatitis C is required
-
Known history of active TB (Bacillus Tuberculosis)
-
History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with subject's participation for the full duration of the study, or make it not in the best interest of the subject to participate, in the opinion of the treating physician
-
Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
-
History of allogenic tissue or solid organ transplant
-
History of active autoimmune disease requiring systemic therapy within the past 12 months, with the exception of ICI induced irAEs.
-
Has not been treated with secukinumab within the last 12 months
-
History of prior cardiac, neurologic, ocular IRAE related to ICI; history of blistering cutaneous IRAE related to ICI
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Secukinumab
Participants will first undergo pre-treatment with secukinumab (300mg subcutaneously) within 1 to 7 days prior to resumption of ICI treatment. Participants will then undergo anti-PD-1 therapy, anti PD-1 plus anti LAG3 (relatlimab) or anti-PD-1 plus anti CTLA-4 therapy at the discretion of their treating physician. Participants will concurrently receive secukinumab 300mg subcutaneously weekly for the first 4 weeks of treatment and then every 4 weeks. |
Secukinumab 300mg subcutaneously |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Safety of administering an IL-17A (human IgG1κ) monoclonal antibody (secukinumab) as determined by occurrence of immune-related Adverse Events (irAEs)
기간: Until grade 3 side effect occurs or three years, whichever comes first
|
Participants will be assessed for AEs at each study visit. AEs are graded by NCI-CTCAE v5.0 criteria. |
Until grade 3 side effect occurs or three years, whichever comes first
|
|
Feasibility of administering an IL-17A (human IgG1κ) monoclonal antibody (secukinumab) as determined by occurrence of immune-related Adverse Events (irAEs)
기간: Until grade 3 side effect occurs or three years, whichever comes first
|
Participants will be assessed for AEs at each study visit. AEs are graded by NCI-CTCAE v5.0 criteria. |
Until grade 3 side effect occurs or three years, whichever comes first
|
공동 작업자 및 조사자
스폰서
수사관
- 수석 연구원: April Salama, MD, Duke University
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- Pro00118701
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .